GlassScriptPhysician profile
Suzanne Y Succop
NPI 1578583076
$11,830.76
in general payments reported to CMS, 2019-2025
23 companies · $2,483 in 2025
The $2,483 reported for 2025 was more than what 87% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $738 · 2020: $645 · 2021: $2,021 · 2022: $884 · 2023: $1,657 · 2024: $3,401 · 2025: $2,483.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,520 · Education: $21.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,520.30 |
| Education | $21.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $4,025.79 | 2019-2025 | Dovato, Apretude, Cabenuva |
| Gilead Sciences, INC. | $2,569.01 | 2019-2025 | Descovy, Yeztugo, Biktarvy |
| Janssen Biotech, INC. | $1,173.07 | 2019-2023 | Symtuza |
| Merck Sharp & Dohme LLC | $911.54 | 2019-2025 | Pifeltro, Delstrigo, Dificid |
| Insmed, INC. | $696.24 | 2019-2025 | Arikayce, Brinsupri |
| Melinta Therapeutics, LLC | $433.58 | 2020-2025 | Rezzayo, Orbactiv, Kimyrsa |
| Abbvie INC. | $418.62 | 2021-2025 | |
| Paratek Pharmaceuticals, INC. | $299.61 | 2019-2025 | Nuzyra |
| Theratechnologies INC. | $250.07 | 2019-2025 | Trogarzo, Egrifta |
| Cipla USA INC. | $212.82 | 2021 | |
| Shionogi INC | $167.73 | 2021-2025 | Fetroja |
| Cumberland Pharmaceuticals, INC. | $122.88 | 2021 | |
| Janssen Products, LP | $121.87 | 2023 | Symtuza |
| Emd Serono, INC. | $102.85 | 2019-2025 | |
| Vyera Pharmaceuticals, LLC | $79.60 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| La Jolla Pharmaceutical Company | $75.39 | 2021-2022 | |
| Allergan, INC. | $51.63 | 2020 | |
| Astellas Pharma US INC | $41.99 | 2021 | |
| Tetraphase Pharmaceuticals, INC. | $20.06 | 2019 | |
| Hologic Sales and Service, LLC | $17.30 | 2025 | Thinprep 2000 Processor, Aptima |
| Nabriva Therapeutics, Plc | $14.08 | 2021 | |
| Janssen Pharmaceuticals, INC | $12.76 | 2021 | |
| Mayne Pharma Commercial LLC | $12.27 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzanne Succop listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.